-
1 Comment
CalAmp Corp is currently in a long term uptrend where the price is trading 9.9% above its 200 day moving average.
From a valuation standpoint, the stock is 95.6% cheaper than other stocks from the Technology sector with a price to sales ratio of 1.1.
CalAmp Corp's total revenue sank by 8.9% to $88M since the same quarter in the previous year.
Its net income has increased by 99.7% to $-24K since the same quarter in the previous year.
Finally, its free cash flow grew by 307.0% to $7M since the same quarter in the previous year.
Based on the above factors, CalAmp Corp gets an overall score of 4/5.
| CurrencyCode | USD |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NASDAQ |
| ISIN | US13463J1016 |
| PE Ratio | None |
|---|---|
| Target Price | 19.9075 |
| Beta | nan |
| Market Cap | 103M |
| Dividend Yield | None |
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001, which is in a Phase 1 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CAMP using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
